Sinovac Biotech receives noncompliance notification from Nasdaq

Sinovac Biotech (SVA) announced that it received a notification letter from Nasdaq, stating that the company was not in compliance with Nasdaq Listing Rule 5250 since the company did not timely file its annual report on Form 20-F for the year ended December 31, 2024. Pursuant to the Nasdaq Listing Rules, the company has 60 calendar days from the date of the Notification Letter, or until July 15, to submit a plan to regain compliance. If Nasdaq accepts the compliance plan, it may grant the company an exception until November 11 to regain compliance. If Nasdaq does not accept the compliance plan, the company will have the opportunity to appeal that decision to a hearing panel under Nasdaq Listing Rule 5815.